Completed PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT05259696

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) (GLIMMER-01)

A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Cancers

Sponsor: Palleon Pharmaceuticals, Inc.

Conditions Bladder Cancer Breast Cancer CRC Cancer Colon Cancer Colorectal Cancer EGJ Esophagogastric Junction Cancer Gastric Cancer Head and Neck Cancer Melanoma NSCLC Non Small Cell Lung Cancer Oncology Ovarian Cancer Pancreatic Cancer Urothelial Cancer

Interventions Cemiplimab E-602

Updated 15 times since 2022 Last updated: Aug 3, 2025 Started: Feb 11, 2022 Primary completion: Oct 24, 2024 Completion: Oct 24, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Bladder Cancer and Breast Cancer and is currently completed. Palleon Pharmaceuticals, Inc. leads this study, which shows 15 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

15 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Apr 2025 — Sep 2025 [monthly]

Completed PHASE1/PHASE2

Status: Active Not Recruiting → Completed
Sep 2024 — Apr 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2

Status: Recruiting → Active Not Recruiting
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 10 earlier versions

Jan 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Sep 2023 — Jan 2024 [monthly]

Recruiting PHASE1_PHASE2
Mar 2023 — Sep 2023 [monthly]

Recruiting PHASE1_PHASE2
Dec 2022 — Mar 2023 [monthly]

Recruiting PHASE1_PHASE2
Sep 2022 — Dec 2022 [monthly]

Recruiting PHASE1_PHASE2
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE1_PHASE2
Jun 2022 — Jul 2022 [monthly]

Recruiting PHASE1_PHASE2
May 2022 — Jun 2022 [monthly]

Recruiting PHASE1_PHASE2
Apr 2022 — May 2022 [monthly]

Recruiting PHASE1_PHASE2
Mar 2022 — Apr 2022 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Feb 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Palleon Pharmaceuticals, Inc.

Data source: Palleon Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States , Buffalo, United States , Fairfax, United States , Grand Rapids, United States , La Jolla, United States , Los Angeles, United States , Nashville, United States , New Haven, United States , New York, United States , Pittsburgh, United States and 3 more locations